0.98
+0.0625(+6.79%)
Currency In USD
Address
200 Clarendon Street
Boston, MA 02116
United States of America
Phone
650 503 9095
Website
Sector
Healthcare
Industry
Biotechnology
Employees
143
First IPO Date
January 26, 2018
| Name | Title | Pay | Year Born |
| Mr. Chen Schor BA, CPA, M.B.A. | Chief Executive Officer, President & Director | 871,968 | 1972 |
| Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 45,000 | 1955 |
| Mr. Brian Nicholas Harvey | Chief Financial Officer | 594,938 | 1961 |
| Dr. Donald Healey Ph.D. | Chief Technology Officer | 606,337 | 1962 |
| Dr. Blake Aftab Ph.D. | Senior Vice President & Chief Scientific Officer | 675,039 | 1981 |
| Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior Vice President | 680,365 | 1968 |
| Ms. Amy Locke | Chief Human Resource Officer | 0 | N/A |
| Dr. Nancy L. Boman M.D., Ph.D. | Senior Vice President & Chief Regulatory Officer | 0 | N/A |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.